@article{uneatlantico510,
          number = {3},
         journal = {Human Reproduction},
           title = {Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area},
            year = {2020},
          volume = {36},
          author = {Ana Teresa Marcos Rodr{\'i}guez and Jos{\'e} Manuel Navarro-Pando},
           pages = {827--829},
           month = {Diciembre},
             url = {http://repositorio.uneatlantico.es/id/eprint/510/},
        abstract = {Sir,

In their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered.

Firstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors? experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8 weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al....}
}